Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm

- High potency (at nanomolar concentration) against MERTK, a promising I-O target; - Overcomes AXL/c-MET mediated resistance to EGFR-directed therapies in NSCLC in vivo; - Ready for IND submission in 2018

via Technology - United States - Latest News http://ift.tt/2jYbQfb